儿童成熟B淋巴细胞白血病7例临床分析

发布时间：2018-09-18 13:44

【摘要】：目的:评估2014年中国抗癌协会儿科专业委员会联合中华医学会儿科学分会血液学组制定的儿童和青少年成熟B细胞非霍奇金淋巴瘤方案(CCCG-BNHL-2015方案)治疗儿童成熟B淋巴细胞白血病的疗效。方法:对本院2014年11月至2017年1月初诊的成熟B淋巴细胞白血病患儿,采用CCCG-BNHL-2015(R4组)方案治疗。结果:纳入统计的成熟B淋巴细胞白血病患儿共7例,中位发病年龄为7.2(4.1-11.75)岁;男性患儿5例,女性患儿2例;其中4例合并胸腔和/或腹腔肿块,1例仅累及淋巴结,2例合并骨质破坏,1例合并中枢神经系统白血病,2例疾病初期出现肿瘤溶解综合征;所有患儿首次乳酸脱氢酶(LDH)检查均显著增高。7例患儿均在2-4个疗程后获得完全缓解,其中2例在疗程结束后行自体造血干细胞移植,1例在所有疗程尚未结束时出现中枢神经系统白血病复发而放弃治疗,其余6例患儿均存活,平均随访时间14(7-28)个月,所有患儿化疗后均出现不同程度的骨髓抑制和感染,无治疗相关性死亡,无严重治疗相关并发症发生。结论:本研究采用的CCCGBNHL-2015方案(R4组)的治疗效果良好、安全性高,完全缓解率高,无治疗相关死亡和严重并发症发生。
[Abstract]:Objective: to evaluate the treatment of mature B-cell non-Hodgkin 's lymphoma in children and adolescents (CCCG-BNHL-2015 regimen) developed in 2014 by the Pediatrics Committee of the Chinese Anti-Cancer Association and the Hematology Group of the Chinese Academy of Pediatrics. Therapeutic effect of lymphocytic leukemia. Methods: children with mature B lymphocyte leukemia from November 2014 to January 2017 were treated with CCCG-BNHL-2015 regimen. Results: there were 7 cases of mature B lymphocytic leukemia, the median onset age was 7.2 (4.1-11.75) years old, 5 cases were male, 2 cases were female, 5 cases were male and 2 cases were female. Of them, 4 cases were associated with thoracic and / or peritoneal masses, 1 case only involved lymph nodes, 2 cases with bone destruction, 1 case with central nervous system leukemia and 2 cases with tumor lysis syndrome at the beginning of the disease. All the patients had a significant increase in lactate dehydrogenase (LDH) (LDH) in the first time. All the patients achieved complete remission after 2-4 courses of treatment. Two of them received autologous hematopoietic stem cell transplantation after the end of the course of treatment. One patient gave up the treatment before the end of all courses of treatment. The other 6 patients survived, with an average follow-up time of 14 (7-28) months. All the children had different degrees of bone marrow suppression and infection after chemotherapy, no treatment-related death, no serious treatment-related complications. Conclusion: the CCCGBNHL-2015 regimen used in this study (R4 group) has good efficacy, high safety, high complete remission rate, no treatment-related death and serious complications.
【作者单位】：南京医科大学附属儿童医院血液肿瘤科;
【基金】：南京市医学科技发展基金资助
【分类号】：R733.71

【相似文献】